The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Harrison SJ et al. Am J Hematol. 2015 Feb 4. doi: 10.1002/ajh.23967. [Epub ahead of print].
